Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 122Cr 104.5Cr 98Cr 90Cr 167.98Cr 12TCr 170.2Cr 1.16TCr 450.51Cr 5.86TCr 458.09Cr 448.12Cr 19TCr P/E 2026 *
-8.8x
P/E 2027 * -7.54x
Enterprise Value 122Cr 104.5Cr 98Cr 90Cr 167.98Cr 12TCr 170.2Cr 1.16TCr 450.51Cr 5.86TCr 458.09Cr 448.12Cr 19TCr EV / Sales 2026 *
22.7x
EV / Sales 2027 * 21.4x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -
1 day-3.25%
1 week-7.74%
Current month-13.44%
1 month-39.89%
3 months-23.98%
6 months-24.66%
Current year-8.80%
1 week 14.17
Extreme 14.17
16.2
1 month 14.17
Extreme 14.17
24.17
Current year 13.69
Extreme 13.69
25.77
1 year 4.54
Extreme 4.54
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2020
Chief Tech/Sci/R&D Officer - 17/03/2026
Chief Operating Officer 54 01/03/2021
Director TitleAgeSince
Director/Board Member 55 01/01/2020
Director/Board Member 49 01/04/2020
Director/Board Member 57 01/06/2020
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-9,500 0.0112%
15/07/26 Fiscal year

Chief Operating Officer

13,053 0.0155%
06/07/26 Fiscal year

Chief Technology Officer

18,000 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
-3.25%-7.74%+196.68%+125.55% 122Cr
+1.09%+5.26%+4.52%+26.24% 5.16TCr
-1.07%+2.82%+465.96%+586.75% 4.49TCr
+1.47%+9.79%+35.92%+21.40% 4.28TCr
+1.44%+7.77%+19.38%+92.75% 4.26TCr
-0.93%-4.33%+16.18%+53.76% 3.18TCr
+1.32%+7.30%+33.89%+150.10% 1.73TCr
-0.60%+1.93% - - 1.66TCr
+0.03%+3.41%+6.55%+32.10% 1.48TCr
+1.28%+5.41%+82.40%+47.43% 1.41TCr
Average +0.08%+3.22%+95.72%+126.23% 2.78TCr
Weighted average by Cap. +0.47%+4.66%+100.03%+146.20%

Financials

2026 *2027 *
Net sales 5.37Cr 4.6Cr 4.3Cr 3.94Cr 7.39Cr 513.51Cr 7.49Cr 51Cr 20Cr 257.96Cr 20Cr 20Cr 853.22Cr 5.71Cr 4.89Cr 4.57Cr 4.19Cr 7.86Cr 546.02Cr 7.96Cr 54Cr 21Cr 274.29Cr 21Cr 21Cr 907.24Cr
Net income -16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -23Cr -155.48Cr -61Cr -789.19Cr -62Cr -60Cr -2.61TCr -20Cr -17Cr -16Cr -15Cr -28Cr -1.93TCr -28Cr -190.64Cr -74Cr -967.63Cr -76Cr -74Cr -3.2TCr
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
173
Date Price Change Volume
21/26/21 $14.30 -3.25% 9,69,159
20/26/20 $14.78 -6.28% 10,21,633
19/26/19 $15.77 +4.92% 10,70,233
18/26/18 $15.03 -2.28% 11,31,845
17/26/17 $15.38 -0.77% 8,15,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
14.30USD
Average target price
28.50USD
Spread / Average Target
+99.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock